Page last updated: 2024-09-05

orantinib and Carcinoma, Lewis Lung

orantinib has been researched along with Carcinoma, Lewis Lung in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cao, C; Choy, H; Donnelly, E; Geng, L; Hallahan, DE; Lu, B; McMahon, G; Musiek, A; Tan, J	1

Other Studies

1 other study(ies) available for orantinib and Carcinoma, Lewis Lung

Article	Year
Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. International journal of radiation oncology, biology, physics, 2004, Mar-01, Volume: 58, Issue:3 Topics: Animals; Carcinoma, Lewis Lung; Cell Line, Tumor; Drug Evaluation, Preclinical; Endothelium, Vascular; Enzyme Activation; Humans; Indoles; Mice; Mice, Inbred C57BL; Oxindoles; Phosphorylation; Propionates; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor Protein-Tyrosine Kinases	2004

Article

Year

Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium.

International journal of radiation oncology, biology, physics, 2004, Mar-01, Volume: 58, Issue:3

Topics: Animals; Carcinoma, Lewis Lung; Cell Line, Tumor; Drug Evaluation, Preclinical; Endothelium, Vascular; Enzyme Activation; Humans; Indoles; Mice; Mice, Inbred C57BL; Oxindoles; Phosphorylation; Propionates; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor Protein-Tyrosine Kinases

2004